Analysts Set Insmed, Inc. (NASDAQ:INSM) Price Target at $149.06

Insmed, Inc. (NASDAQ:INSM) has received an average rating of “Moderate Buy” from the twenty-one research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and nineteen have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $149.0625.

INSM has been the topic of several research reports. Morgan Stanley boosted their price target on shares of Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. Truist Financial lifted their price objective on shares of Insmed from $126.00 to $139.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Jefferies Financial Group lifted their price objective on shares of Insmed from $129.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, August 13th. Evercore ISI reaffirmed an “outperform” rating and set a $180.00 price objective on shares of Insmed in a research note on Wednesday, October 1st. Finally, Mizuho lifted their price objective on shares of Insmed from $130.00 to $165.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 13th.

Insmed Trading Up 1.0%

Shares of INSM opened at $163.94 on Thursday. The company’s fifty day moving average is $139.14 and its 200 day moving average is $102.76. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $166.44. The stock has a market capitalization of $34.65 billion, a PE ratio of -28.71 and a beta of 1.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. During the same quarter in the prior year, the firm posted ($1.94) EPS. The company’s revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Activity at Insmed

In other Insmed news, CFO Sara Bonstein sold 58,400 shares of Insmed stock in a transaction on Monday, July 21st. The shares were sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the completion of the transaction, the chief financial officer directly owned 73,505 shares of the company’s stock, valued at $7,546,758.35. The trade was a 44.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Alexander Smith sold 24,272 shares of Insmed stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total transaction of $3,492,498.08. Following the transaction, the insider directly owned 54,902 shares of the company’s stock, valued at $7,899,848.78. The trade was a 30.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 211,057 shares of company stock valued at $27,438,126 over the last three months. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Insmed

A number of large investors have recently made changes to their positions in INSM. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Insmed by 10.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,231 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 307 shares during the period. NBC Securities Inc. purchased a new stake in shares of Insmed during the first quarter valued at $49,000. Park Avenue Securities LLC boosted its stake in shares of Insmed by 38.7% during the first quarter. Park Avenue Securities LLC now owns 11,036 shares of the biopharmaceutical company’s stock valued at $842,000 after purchasing an additional 3,081 shares during the period. Harbor Capital Advisors Inc. boosted its stake in shares of Insmed by 22.2% during the first quarter. Harbor Capital Advisors Inc. now owns 72,816 shares of the biopharmaceutical company’s stock valued at $5,555,000 after purchasing an additional 13,216 shares during the period. Finally, GAMMA Investing LLC boosted its stake in shares of Insmed by 62.0% during the first quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 386 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.